Norway vs Tunisia: HIV/AIDS deaths averted by antiretroviral therapy
Norway
168.96 deaths
in 2024
Tunisia
198.78 deaths
in 2024
Norway rank
113th
Tunisia rank
110th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Norway
- Tunisia
How they compare
Tunisia currently reports 198.78 deaths against 168.96 deaths in Norway, a difference of 29.82 deaths.
That makes Tunisia's figure about 1.2 times Norway's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Tunisia ahead.
Norway ranks 113th and Tunisia ranks 110th of 157 countries.
Norway has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Norway | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 24.26 deaths | 0 deaths | 24.26 deaths | Norway |
| 2000s | 111.82 deaths | 23.7 deaths | 88.12 deaths | Norway |
| 2010s | 182.68 deaths | 81.37 deaths | 101.3 deaths | Norway |
| 2020s | 180.2 deaths | 164.95 deaths | 15.25 deaths | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Norway or Tunisia?
- Tunisia, at 198.78 deaths against 168.96 deaths in Norway as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Norway and Tunisia?
- 29.82 deaths, with Tunisia ahead.
- How many years of comparable data are there for Norway and Tunisia?
- 35 years are reported by both, from 1990 to 2024.
- How do Norway and Tunisia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Norway ranks 113th and Tunisia ranks 110th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.